Sign In
Buy MRK
$119.05
-1.73 (-1.43%)
At Close: Jun 12, 2026
Wall Street Roundup: Risk Off
01:25pm, Friday, 06'th Feb 2026
Risk-off sentiment is driving sharp sell-offs in Bitcoin and major software stocks, with investors reallocating away from stretched tech valuations. AI-driven CapEx arms race at Alphabet (GOOGL) and A
Merck's Subdued 2026 Outlook: What it Means After Q4 Results?
12:06pm, Friday, 06'th Feb 2026
MRK posts conservative 2026 sales and EPS outlook, given acquisition charges. Keytruda, Animal Health and new drug launches are expected to drive 2026 growth.
Market Today: Amazon capex, AI selloff, Disney CEO shift
05:36pm, Thursday, 05'th Feb 2026
Stock News Amazon lifts 2026 capex to ~$200B: Amazon (AMZN) posted a Q4 EPS miss but revenue beat and guided 2026 capital expenditures to about $200 billion, pr
Merck & Co., Inc. (NYSE:MRK) Trading Up 2.2% After Earnings Beat
02:26am, Thursday, 05'th Feb 2026
Merck and Co., Inc. (NYSE: MRK - Get Free Report) shares rose 2.2% on Wednesday following a better than expected earnings announcement. The company traded as high as $120.39 and last traded at $118.35
CANCER BREAKTHROUGH: Moderna, Merck report cancer discovery
08:15am, Wednesday, 04'th Feb 2026
Moderna CEO Stéphane Bancel discusses positive cancer vaccine trial results and the impact GLP-1 drugs on 'Mornings with Maria.' #foxbiusiness #morningswithmaria
Merck & Co Inc (MRK) Q4 2025 Earnings Call Highlights: Strong Growth Amidst Challenges
04:02pm, Tuesday, 03'rd Feb 2026
Release Date: February 03, 2026For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Merck and Co I
Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript
01:30pm, Tuesday, 03'rd Feb 2026
Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript
MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View
12:40pm, Tuesday, 03'rd Feb 2026
Merck tops Q4 EPS and sales estimates as Keytruda drives growth, but shares fall in pre-market trading as 2026 guidance disappoints.
Merck (MRK) Reports Q4 Earnings: What Key Metrics Have to Say
12:01pm, Tuesday, 03'rd Feb 2026
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street
Stock Market Today: Major Indexes Decline; Dow Sets New All-Time High Before Pulling Back; Gold, Silver Rebound
12:00pm, Tuesday, 03'rd Feb 2026
Major equities indexes fell Tuesday, although the Dow Jones Industrial Average hit a new all-time high before slipping. Meanwhile, gold and silver futures resumed their ascent.
Merck's Annual Outlook Falls Short But Keytruda, Animal Health Segments Grow
11:06am, Tuesday, 03'rd Feb 2026
Merck & Co., Inc. (NYSE: MRK) on Tuesday reported its fourth-quarter adjusted earnings per share of $2.04, surpassing consensus estimates of $2.01, a jump from $1.72 a year ago.
2 Pharma Stocks React to Quarterly Results, Guidance
11:04am, Tuesday, 03'rd Feb 2026
Pfizer Inc (NYSE:PFE) shares are down 3.2% to trade at $25.40 at last check, despite surpassing earnings and revenue expectations for the fourth quarter.
Merck shares dip as 2026 outlook misses Wall Street expectations
09:43am, Tuesday, 03'rd Feb 2026
Merck & Co Inc (NYSE:MRK, XETRA:6MK) shares fell 2% at Tuesday's opening bell after the drugmaker issued a 2026 outlook that came in below Wall Street expectations, overshadowing a fourth-quarter earn
Merck (MRK) Q4 Earnings and Revenues Beat Estimates
08:41am, Tuesday, 03'rd Feb 2026
Merck (MRK) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.72 per share a year ago.
Merck tops Q4 earnings expectations but issues weaker 2026 outlook
07:14am, Tuesday, 03'rd Feb 2026
Merck closed the fourth quarter with earnings and revenue ahead of Wall Street estimates, supported by strong demand for its blockbuster cancer drug Keytruda and accelerating sales from newer medicine
